What’s ABIOMED, Inc. (ABMD) Upside After Achieving 52-Week High?

June 20, 2017 - By Richard Conner

Investors sentiment increased to 1.01 in Q4 2016. Its up 0.03, from 0.98 in 2016Q3. It increased, as 36 investors sold ABIOMED, Inc. shares while 102 reduced holdings. 40 funds opened positions while 100 raised stakes. 37.23 million shares or 0.30% less from 37.34 million shares in 2016Q3 were reported.
Eagle Asset Mngmt Inc holds 159,327 shares. Citigroup, New York-based fund reported 2,208 shares. 2,280 are owned by Riverhead Mgmt Lc. Comerica Financial Bank accumulated 29,970 shares or 0.03% of the stock. Oberweis Asset Mngmt holds 1.25% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 37,050 shares. Commonwealth Of Pennsylvania Public School Empls Retrmt accumulated 0.01% or 5,973 shares. Oregon Public Employees Retirement Fund reported 13,838 shares or 0.03% of all its holdings. Qs Investors Limited Liability Corporation has invested 0% in ABIOMED, Inc. (NASDAQ:ABMD). Balasa Dinverno & Foltz Llc invested in 3,020 shares. Advsr Asset holds 20,126 shares or 0.04% of its portfolio. 1,301 were reported by Paradigm Asset Mngmt Lc. Moreover, Voya Invest Mngmt Limited Company has 0.06% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 222,221 shares. Fortaleza Asset Mngmt holds 1.58% or 6,630 shares in its portfolio. Alliancebernstein Ltd Partnership accumulated 43,806 shares. Brown Capital Mgmt Ltd Llc invested in 701,811 shares.

Since February 6, 2017, it had 0 insider buys, and 6 insider sales for $10.61 million activity. $2.30M worth of ABIOMED, Inc. (NASDAQ:ABMD) shares were sold by Weber David M. The insider Howley Michael G sold $2.44M. 13,500 shares were sold by PUHY DOROTHY E, worth $1.77 million. Shares for $1.24M were sold by Greenfield Andrew J on Friday, March 17.

The stock of ABIOMED, Inc. (NASDAQ:ABMD) hit a new 52-week high and has $152.43 target or 4.00 % above today’s $146.57 share price. The 9 months bullish chart indicates low risk for the $6.54 billion company. The 1-year high was reported on Jun, 20 by Barchart.com. If the $152.43 price target is reached, the company will be worth $261.60M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

About 7,600 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 40.97% since June 20, 2016 and is uptrending. It has outperformed by 24.27% the S&P500.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Among 8 analysts covering Abiomed (NASDAQ:ABMD), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Abiomed has $145 highest and $80 lowest target. $125’s average target is -14.72% below currents $146.57 stock price. Abiomed had 13 analyst reports since August 4, 2015 according to SRatingsIntel. As per Tuesday, August 4, the company rating was maintained by Benchmark. The rating was maintained by Northland Capital on Wednesday, August 5 with “Market Perform”. Piper Jaffray maintained the stock with “Hold” rating in Wednesday, August 5 report. Jefferies maintained the stock with “Buy” rating in Tuesday, August 9 report. Sterne Agee CRT initiated ABIOMED, Inc. (NASDAQ:ABMD) on Tuesday, August 18 with “Buy” rating. Raymond James upgraded the shares of ABMD in report on Friday, October 30 to “Outperform” rating. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Hold” rating by BTIG Research on Tuesday, August 4. Guggenheim initiated ABIOMED, Inc. (NASDAQ:ABMD) on Wednesday, December 7 with “Buy” rating. The firm has “Overweight” rating given on Thursday, April 6 by PiperJaffray. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Outperform” rating by Leerink Swann on Wednesday, May 4.

More recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Nasdaq.com which released: “Abiomed Inc (ABMD) Files 10-K for the Fiscal Year Ended on March 31, 2017” on May 25, 2017. Also Nasdaq.com published the news titled: “Abiomed (ABMD) at 52-Week High: What’s Driving the Stock?” on June 06, 2017. Globenewswire.com‘s news article titled: “Abiomed to Present at the Jefferies Healthcare Conference” with publication date: May 30, 2017 was also an interesting one.

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The company has market cap of $6.54 billion. The Firm offers care to heart failure patients. It has a 126.16 P/E ratio. The Firm operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.